QR Pharma Receives FDA Clearance to Conduct Clinical Trials with Its Second Novel Alzheimer Compound, Bisnorcymserine
12/2/2010 10:41:12 AM
RADNOR, Pa.--(BUSINESS WIRE)--QR Pharma, Inc., a developer of novel drugs to treat Alzheimer’s disease (AD), announced today that the United States Food and Drug Administration (FDA) has accepted the Investigational New Drug application (IND) to begin human clinical trials and evaluate the safety and efficacy of the company’s second product, bisnorcymserine (BNC). “Receiving clearance to move into clinical studies for BNC is a significant milestone for QR Pharma,” said Maria Maccecchini, CEO of QR Pharma.
comments powered by